- Home
- ELMD vs ZNTL Comparison
ELMD vs ZNTL Comparison
Compare ELMD & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELMD | ZNTL |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 195.8M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELMD | ZNTL |
|---|---|---|
| Price | $24.27 | $6.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $36.00 | $5.80 |
| AVG Volume (30 Days) | 40.1K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | 18.03 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $54,716,000.00 | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $43.59 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $17.73 | $1.13 |
| 52 Week High | $30.73 | $4.50 |
Technical Indicators
Market Signals| Indicator | ELMD | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 87.82 |
| Support Level | $23.29 | $1.31 |
| Resistance Level | $25.31 | N/A |
| Average True Range (ATR) | 0.85 | 0.48 |
| MACD | 0.12 | 0.34 |
| Stochastic Oscillator | 60.45 | 94.98 |
Price Performance
Historical ComparisonAbout ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.